Q-omics provides the consensus-scored MAFK profile across patient tissues and cancer cell-line models. MAFK expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MAFK is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MAFK RNA expression shows 19,300 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, HNSC, and ACC as cancer lineages where MAFK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAFK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAFK survival associations across molecular data types. MAFK RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAFK RNA expression–survival associations across cancer types. High MAFK expression shows unfavorable associations in LUAD, CESC, LGG and COAD, but favorable associations in SKCM and THYM. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MAFK RNA expression.
This table summarizes MAFK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAFK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAFK shows lower tumor expression in BLCA, UCEC, BRCA and LUSC and higher tumor expression in HNSC and COAD. The HNSC box plot shows higher MAFK RNA expression in tumor versus normal tissue (log2 FC = +1.143, t-test p < 0.001).
This table shows molecular features associated with MAFK in patient tissues and cancer cell lines. In patient samples, MAFK shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAFK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
